{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=20", "query": { "intervention": "Placebo (treatment C)", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 988, "total_pages": 99, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28treatment+C%29&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T22:25:11.367Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07383441", "title": "Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Axitinib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Clostridium butyricum CBM 588 Probiotic Strain", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab and Recombinant Human Hyaluronidase", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo Administration", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 718, "start_date": "2026-06-05", "completion_date": "2034-01-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-15T22:25:11.367Z", "location_count": 41, "location_summary": "Fayetteville, Arkansas • Jonesboro, Arkansas • Rogers, Arkansas + 36 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Bloomington", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT07383441" }, { "nct_id": "NCT00220779", "title": "Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis, Relapsing-Remitting" ], "interventions": [ { "name": "Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified", "type": "DRUG" }, { "name": "Albumin (Human) 25%, United States Pharmacopeia (USP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 128, "start_date": "2002-12", "completion_date": "2005-02", "has_results": true, "last_update_posted_date": "2016-04-27", "last_synced_at": "2026-10-15T22:25:11.367Z", "location_count": 6, "location_summary": "Phoenix, Arizona • Tucson, Arizona • New York, New York + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "New York", "state": "New York" }, { "city": "Stony Brook", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00220779" }, { "nct_id": "NCT03679676", "title": "Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypersensitivity", "Food Allergy", "Hypersensitivity, Food", "Peanut Hypersensitivity", "Peanut Allergy" ], "interventions": [ { "name": "Omalizumab", "type": "DRUG" }, { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo for Dupilumab", "type": "OTHER" }, { "name": "Placebo for Omalizumab", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "4 Years to 55 Years" }, "enrollment_count": 130, "start_date": "2020-02-05", "completion_date": "2025-05-02", "has_results": true, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-15T22:25:11.367Z", "location_count": 3, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03679676" }, { "nct_id": "NCT04276259", "title": "Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Major Depressive Disorder", "Depression" ], "interventions": [ { "name": "Buprenorphine", "type": "DRUG" }, { "name": "Naltrexone", "type": "DRUG" }, { "name": "Oral Placebo", "type": "DRUG" }, { "name": "IM Placebo", "type": "DRUG" }, { "name": "Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Marta Peciña, MD PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 120, "start_date": "2020-10-19", "completion_date": "2026-03-31", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-15T22:25:11.367Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04276259" }, { "nct_id": "NCT05360446", "title": "Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Inclisiran sodium 300 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 610, "start_date": "2022-07-08", "completion_date": "2026-10-26", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-15T22:25:11.367Z", "location_count": 27, "location_summary": "Huntsville, Alabama • Anchorage, Alaska • Beverly Hills, California + 22 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05360446" }, { "nct_id": "NCT03049462", "title": "The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Polycystic Ovary Syndrome" ], "interventions": [ { "name": "Mirabegron", "type": "DRUG" }, { "name": "B Complex Plus Vitamin C Tablets", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 55, "start_date": "2017-03-13", "completion_date": "2026-08-26", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-15T22:25:11.367Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049462" }, { "nct_id": "NCT01265017", "title": "Role of Pregnancy Related Hormones in Lowering the Insulin Requirement in Pregnant Women With Type 1 Diabetes", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "Estradiol, medroxyprogesterone, hydrocortisone, GH", "type": "DRUG" }, { "name": "Matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sansum Diabetes Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2012-07", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2018-04-18", "last_synced_at": "2026-10-15T22:25:11.367Z", "location_count": 1, "location_summary": "Santa Barbara, California", "locations": [ { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01265017" }, { "nct_id": "NCT01191723", "title": "QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "MAP0004", "type": "DRUG" }, { "name": "Inhaler Placebo", "type": "DRUG" }, { "name": "Moxifloxacin", "type": "DRUG" }, { "name": "Placebo Capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 54, "start_date": "2010-08", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2014-01-09", "last_synced_at": "2026-10-15T22:25:11.367Z", "location_count": 1, "location_summary": "Fargo, North Dakota", "locations": [ { "city": "Fargo", "state": "North Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191723" }, { "nct_id": "NCT01794923", "title": "Topical Ibuprofen for Delayed Onset Mulscle Soreness", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain" ], "interventions": [ { "name": "IBU BID", "type": "DRUG" }, { "name": "Placebo BID", "type": "DRUG" }, { "name": "IBU TID", "type": "DRUG" }, { "name": "Placebo TID", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 205, "start_date": "2013-06-13", "completion_date": "2014-03-29", "has_results": true, "last_update_posted_date": "2021-09-30", "last_synced_at": "2026-10-15T22:25:11.367Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01794923" }, { "nct_id": "NCT06929923", "title": "Pro-2-Cool Pivotal Trial II", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Concussion, Mild" ], "interventions": [ { "name": "Pro2Cool Device", "type": "DEVICE" }, { "name": "Sham Cooling Garment Device", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "TecTraum Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "13 Years to 21 Years" }, "enrollment_count": 66, "start_date": "2025-02-20", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-15T22:25:11.367Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Akron, Ohio • Cleveland, Ohio", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Akron", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06929923" } ] }